Pictet North America Advisors SA Buys New Stake in SPDR S&P Biotech ETF $XBI

Pictet North America Advisors SA purchased a new position in SPDR S&P Biotech ETF (NYSEARCA:XBI) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 6,020 shares of the exchange traded fund’s stock, valued at approximately $734,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. JPMorgan Chase & Co. grew its stake in shares of SPDR S&P Biotech ETF by 27.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 13,538,738 shares of the exchange traded fund’s stock valued at $1,356,582,000 after purchasing an additional 2,900,633 shares during the period. Greenwoods Asset Management Hong Kong Ltd. bought a new position in shares of SPDR S&P Biotech ETF during the 3rd quarter worth approximately $55,613,000. Ameriprise Financial Inc. lifted its position in shares of SPDR S&P Biotech ETF by 123.0% during the 2nd quarter. Ameriprise Financial Inc. now owns 872,796 shares of the exchange traded fund’s stock worth $72,542,000 after buying an additional 481,408 shares during the period. Meitav Investment House Ltd. boosted its stake in SPDR S&P Biotech ETF by 70.3% in the 3rd quarter. Meitav Investment House Ltd. now owns 682,056 shares of the exchange traded fund’s stock valued at $68,156,000 after buying an additional 281,602 shares in the last quarter. Finally, Marshall Wace LLP boosted its stake in SPDR S&P Biotech ETF by 102.3% in the 2nd quarter. Marshall Wace LLP now owns 4,023 shares of the exchange traded fund’s stock valued at $334,000 after buying an additional 179,029 shares in the last quarter.

SPDR S&P Biotech ETF Price Performance

Shares of NYSEARCA:XBI opened at $128.55 on Thursday. The business’s fifty day moving average price is $125.03 and its two-hundred day moving average price is $117.89. SPDR S&P Biotech ETF has a fifty-two week low of $66.66 and a fifty-two week high of $132.09. The stock has a market capitalization of $8.59 billion, a price-to-earnings ratio of 11.47 and a beta of 0.93.

About SPDR S&P Biotech ETF

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.